[논문]Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine

Lee, K. J.; Kim, N. Y.; Kwon, J. K.; Huh, K. C.; Lee, O. Y.; Lee, J. S.; Choi, S. C.; Sohn, C. I.; Myung, S. J.; Park, H. J.; Choi, M. K.; Bak, Y. T.; Rhee, P. L.

doi:10.1111/j.1365-2982.2011.01771.x

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, v.23 no.12, 2011년, pp.1098 - 1104

Lee, K. J. (Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea) , Kim, N. Y. (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea) , Kwon, J. K. (Department of Internal Medicine, Daeku Catholic University College of Medicine, Daeku, Korea) , Huh, K. C. (Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea) , Lee, O. Y. (Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea) , Lee, J. S. (Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea) , Choi, S. C. (Department of Internal Medicine, Wonkwang University College of Medicine, Iksan, Korea) , Sohn, C. I. (Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea) , Myung, S. J. (Department of Internal Medicine, Ulsan University College of Medicine, Ulsan, Korea) , Park, H. J. (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea kn<) , Choi, M. K. , Bak, Y. T. , Rhee, P. L.

Abstract ▼ AI-Helper

AbstractBackground The 5‐HT3 receptor antagonists are known to be effective for the treatment of diarrhea‐predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5‐HT3 receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS‐D).Methods This study was performed in a multicenter, randomized, open‐label design. Data of 343 male patients with IBS‐D who were randomized to either a 4‐week treatment of ramosetron 5 μg once daily or a 4‐week treatment of mebeverine 135 mg three times daily were analyzed by the intent‐to‐treat analysis. The primary efficacy parameter was the proportion of patients with adequate relief of IBS symptoms at the last week of treatment. The secondary endpoints were changes in each symptom score and the safety profiles.Key Results The responder rates for global IBS symptoms, abdominal pain/discomfort and abnormal bowel habits in the ramosetron and mebeverine groups significantly increased during the treatment period. The severity scores of abdominal pain/discomfort and urgency, the stool form score, and the stool frequency in both treatment arms were significantly reduced, compared with the baselines. There were no significant differences in the responder rates (37%vs 38% on ITT analysis) and adverse event profiles between the ramosetron and mebeverine groups. Neither severe constipation nor ischemic colitis was reported by ramosetron‐treated patients.Conclusions & Inferences Ramosetron 5 μg once daily is as effective as mebeverine three times daily in male patients with IBS‐D.

주제어

참고문헌 (19)

Croghan Recognizing and managing patients with irritable bowel syndrome J Am Acad Nurse Pract 2005 10.1111/j.1041-2972.2005.00011.x 17 51

상세보기
Wilson Prevalence of irritable bowel syndrome: a community survey Br J Gen Pract 2004 54 495

상세보기
Gwee The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community Am J Gastroenterol 2004 10.1111/j.1572-0241.2004.04161.x 99 924

상세보기
Saito The epidemiology of irritable bowel syndrome in North America: a systematic review Am J Gastroenterol 2002 97 1910

상세보기
Camilleri Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial Lancet 2000 10.1016/S0140-6736(00)02033-X 355 1035

상세보기
Cremonini Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Neurogastroenterol Motil 2003 10.1046/j.1365-2982.2003.00389.x 15 79

상세보기
Camilleri A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Arch Intern Med 2001 10.1001/archinte.161.14.1733 161 1733

상세보기
Miyata Involvement of the 5-HT3 receptor in CRH-induce defecation in rats Am J Physiol 1998 274 G827
Hirata Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents J Pharmacol Sci 2008 10.1254/jphs.FP0071943 106 264

상세보기
Hirata Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer Neurogastroenterol Motil 2008 10.1111/j.1365-2982.2007.01069.x 20 557

상세보기
Matsueda A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome Digestion 2008 10.1159/000150632 77 225

상세보기
Matsueda A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome Scand J Gastroenterol 2008 10.1080/00365520802240255 43 1202

상세보기
Jones Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients Aliment Pharmacol Ther 1999 10.1046/j.1365-2036.1999.00678.x 13 1419

상세보기
Darvish-Damavandi A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome World J Gastroenterol 2010 10.3748/wjg.v16.i5.547 16 547

상세보기
Longstreth Functional bowel disorders Gastroenterology 2006 10.1053/j.gastro.2005.11.061 130 1480

상세보기
Rabasseda Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting Drugs Today 2002 10.1358/dot.2002.38.2.820104 38 75

상세보기
Gan Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs 2005 10.2165/00023210-200519030-00004 19 225

상세보기
Andresen Effects of 5-HT3 antagonists on symptom relief and constipation in non-constipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Clin Gastroenterol Hepatol 2008 10.1016/j.cgh.2007.12.015 6 545

상세보기
Rahimi Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12-week trials Clin Ther 2008 10.1016/j.clinthera.2008.05.002 30 884

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine

Abstract ▼ AI-Helper

주제어

참고문헌 (19)

이 논문을 인용한 문헌

관련 콘텐츠

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트